Related references
Note: Only part of the references are listed.Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches
Ravi G. Gupta et al.
CANCER DISCOVERY (2021)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Parisa Malekzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer
Tadaaki Yamada et al.
CANCER MEDICINE (2019)
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
Susumu Iiizumi et al.
CANCERS (2019)
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Fangjun Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Davide Bedognetti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters
Arnold J. Levine et al.
CANCER CELL (2019)
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer
Satomi Watanabe et al.
CANCER SCIENCE (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Improved methods for predicting peptide binding affinity to MHC class II molecules
Kamilla Kjaergaard Jensen et al.
IMMUNOLOGY (2018)
Perturbation-response genes reveal signaling footprints in cancer gene expression
Michael Schubert et al.
NATURE COMMUNICATIONS (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
Olivier Bylicki et al.
TARGETED ONCOLOGY (2017)
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Jing Xu et al.
ONCOTARGET (2017)
Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Thomas C. Wirth et al.
FRONTIERS IN IMMUNOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Preclinical and clinical development of neoantigen vaccines
L. Li et al.
ANNALS OF ONCOLOGY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Gapped sequence alignment using artificial neural networks: application to the MHC class I system
Massimo Andreatta et al.
BIOINFORMATICS (2016)
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Yoshihisa Kobayashi et al.
CANCER SCIENCE (2016)
A Novel Method to Detect Functional microRNA Regulatory Modules by Bicliques Merging
Cheng Liang et al.
IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma
Jia-Jie Hao et al.
NATURE GENETICS (2016)
Cancer immunotherapy targeting neoantigens
Yong-Chen Lu et al.
SEMINARS IN IMMUNOLOGY (2016)
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
Abhilash Venugopalan et al.
ONCOTARGET (2016)
Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination
Fenge Li et al.
ONCOIMMUNOLOGY (2016)
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
Jin S. Im et al.
PLOS ONE (2016)
A survey of best practices for RNA-seq data analysis
Ana Conesa et al.
GENOME BIOLOGY (2016)
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Kailong Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells
Willem W. Overwijk
NATURE MEDICINE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Trial Watch: Peptide-based anticancer vaccines
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations
Faviel F. Gonzalez-Galarza et al.
NUCLEIC ACIDS RESEARCH (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Clustering HLA Class I Superfamilies Using Structural Interaction Patterns
Sumitro Harjanto et al.
PLOS ONE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Kevin Becker et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
HLA-F and MHC-I Open Conformers Cooperate in a MHC-I Antigen Cross-Presentation Pathway
Jodie P. Goodridge et al.
JOURNAL OF IMMUNOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
HLA class I supertypes: a revised and updated classification
John Sidney et al.
BMC IMMUNOLOGY (2008)
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond
Cyrille J. Cohen et al.
CANCER RESEARCH (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Interferon-γ:: an overview of signals, mechanisms and functions
K Schroder et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Share Paper
